Stock TYP TRYPTAMINE THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tryptamine Therapeutics Limited

Equities

TYP

AU0000331993

Biotechnology & Medical Research

Delayed Australian S.E.
Other stock markets
 11:40:22 2024-06-18 pm EDT 		5-day change 1st Jan Change
0.02 AUD 0.00% Intraday chart for Tryptamine Therapeutics Limited -4.76% 0.00%
Jun. 19 Tryptamine Therapeutics Partners with Lucid Health to Advance TRP-8803's Product Registration in Australia MT
May. 29 Tryptamine Therapeutics Begins to Trade on ASX; Shares Surge 118% MT

Valuation

Fiscal Period: August 2024 2025 2026
Capitalization 1 26.77 - -
Enterprise Value (EV) 1 26.77 26.77 26.77
P/E ratio - - -
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -
EV / FCF - - -
FCF Yield - - -
Price to Book - - -
Nbr of stocks (in thousands) 1,463,922 - -
Reference price 2 0.0200 0.0200 0.0200
Announcement Date - - -
1AUD in Million2
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: August 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - -
EBITDA - - - - - -
EBIT 1 -7.288 -7.364 -5.246 -5.096 -5.603 -5.883
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -8.255 -7.495 -5.267 -5.096 -5.603 -5.883
Net income 1 -8.255 -7.495 -5.267 -5.096 -5.603 -5.883
Net margin - - - - - -
EPS - - - - - -
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 12/22/21 12/13/22 12/29/23 - - -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: August 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - - - - - - - - -
EBIT 1 -3.01 -1.549 - -2.104 -1.616 -1.266 - -1.593 -1.131 -0.9394 -1.328 -1.517
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -3.001 -1.559 - -2.17 -1.634 -1.287 -0.7838 -1.69 -1.161 -0.9882 -1.328 -1.517
Net income 1 -3 -1.559 -0.7499 -2.17 -1.634 -1.287 -0.6558 -1.69 -1.161 -0.9882 -1.328 -1.517
Net margin - - - - - - - - - - - -
EPS - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 1/28/22 4/29/22 7/28/22 12/13/22 1/25/23 4/28/23 7/31/23 12/29/23 2/5/24 4/29/24 - -
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: August 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 12/22/21 12/13/22 12/29/23 - - -
1CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TRYPTAMINE THERAPEUTICS LIMITED Stock Tryptamine Therapeutics Limited
0.00% 19.46M
MODERNA, INC. Stock Moderna, Inc.
+34.01% 51.07B
LONZA GROUP AG Stock Lonza Group AG
+33.84% 38.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.02% 38.78B
CELLTRION, INC. Stock Celltrion, Inc.
-8.98% 26.69B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.56% 26.35B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.62% 19.46B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+39.18% 13.58B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.47% 12.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.40% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TYP Stock
  4. Financials Tryptamine Therapeutics Limited